Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.68 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.68 |
| ▸ | TP53 | P04637 | 6/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | THRB | P10828 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24106016 | 0.89 | LMNA (0.63) | LMNARXFP1TP53MAPTTHRB | |
| SCHEMBL24106080 | 0.88 | LMNA (0.62) | LMNARXFP1TP53MAPTTHRB | |
| SCHEMBL24105991 | 0.88 | TP53 (0.67) | LMNARXFP1TP53MAPTTHRB | |
| SCHEMBL11037807 | 0.83 | APP (0.72) | LMNARXFP1TP53MAPTTHRB | |
| SCHEMBL29924867 | 0.82 | MAPT (0.81) | LMNARXFP1TP53MAPTTHRB | |
| SCHEMBL24106012 | 0.82 | THRB (0.70) | LMNARXFP1TP53MAPTTHRB | |
| SCHEMBL10000316 | 0.82 | LMNA (0.59) | LMNARXFP1TP53MAPTTHRB | |
| SCHEMBL29925178 | 0.81 | MAPT (0.77) | LMNARXFP1TP53MAPTTHRB | |
| SCHEMBL24741699 | 0.81 | MAPT (0.77) | LMNARXFP1TP53MAPTTHRB | |
| SCHEMBL74730 | 0.81 | MAPT (0.80) | LMNARXFP1TP53MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11559518-B2 | Endoplasmic reticulum stress regulator comprising benzothiazoimidazolyl compound | ER STRESS RESEARCH INSTITUTE, INC. (JP) | 2023-01-24 | — | — | US | disclosed |
| US-20210386715-A1 | ENDOPLASMIC RETICULUM STRESS REGULATOR COMPRISING BENZOTHIAZOIMIDAZOLYL COMPOUND | ER STRESS RESEARCH INSTITUTE, INC. (JP) | 2021-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559518-B2 | Endoplasmic reticulum stress regulator comprising benzothiazoimidazolyl compound | HSPA5, DNAJC10, ERP44 | LMNA 1562/4885RXFP1 3404/4885TP53 1281/4885 |
| US-20210386715-A1 | ENDOPLASMIC RETICULUM STRESS REGULATOR COMPRISING BENZOTHIAZOIMIDAZOLYL COMPOUND | DNAJC10, HSPA5, ERP44 | LMNA 1109/4885RXFP1 3780/4885TP53 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.